These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 12497205

  • 1. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR.
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):43-52. PubMed ID: 12497205
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
    Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR.
    Br J Cancer; 1998 Aug; 78(4):439-45. PubMed ID: 9716024
    [Abstract] [Full Text] [Related]

  • 3. Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
    Siim BG, Laux WT, Rutland MD, Palmer BN, Wilson WR.
    Cancer Res; 2000 Aug 15; 60(16):4582-8. PubMed ID: 10969810
    [Abstract] [Full Text] [Related]

  • 4. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid.
    Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR.
    Int J Radiat Oncol Biol Phys; 1994 May 15; 29(2):373-7. PubMed ID: 8195036
    [Abstract] [Full Text] [Related]

  • 5. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
    Browne WL, Wilson WR, Baguley BC, Ching LM.
    Anticancer Res; 1998 May 15; 18(6A):4409-13. PubMed ID: 9891501
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid.
    Pruijn FB, van Daalen M, Holford NH, Wilson WR.
    Cancer Chemother Pharmacol; 1997 May 15; 39(6):541-6. PubMed ID: 9118467
    [Abstract] [Full Text] [Related]

  • 7. Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
    Murata R, Overgaard J, Horsman MR.
    Int J Hyperthermia; 2001 May 15; 17(6):508-19. PubMed ID: 11719967
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide.
    Kestell P, Zhao L, Baguley BC, Palmer BD, Muller G, Paxton JW, Ching LM.
    Cancer Chemother Pharmacol; 2000 May 15; 46(2):135-41. PubMed ID: 10972483
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy.
    Siemann DW, Mercer E, Lepler S, Rojiani AM.
    Int J Cancer; 2002 May 01; 99(1):1-6. PubMed ID: 11948484
    [Abstract] [Full Text] [Related]

  • 15. In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
    Zhou S, Paxton JW, Kestell P, Tingle MD, Ching LM.
    Cancer Chemother Pharmacol; 2001 Apr 01; 47(4):319-26. PubMed ID: 11345648
    [Abstract] [Full Text] [Related]

  • 16. 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
    Zhou S, Kestell P, Baguley BC, Paxton JW.
    Invest New Drugs; 2002 Aug 01; 20(3):281-95. PubMed ID: 12201491
    [Abstract] [Full Text] [Related]

  • 17. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.
    Murata R, Overgaard J, Horsman MR.
    Int J Radiat Biol; 2001 Feb 01; 77(2):195-204. PubMed ID: 11236926
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid.
    Murata R, Horsman MR.
    Int J Hyperthermia; 2004 Jun 01; 20(4):393-404. PubMed ID: 15204520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.